Pharmacological characterization of the quisqualate receptor coupled to phospholipase C (Qp) in striatal neurons.

A detailed pharmacological characterization of the quisqualate (QA) receptor coupled to phospholipase C (Qp) was performed in striatal neurons. The experiments were carried out in the presence of the ionotropic antagonists MK-801 (1 microM) and 6-cyano-7-nitroquinoxaline-2,3-dione (30 microM), concentrations that block N-methyl-D-aspartate (NMDA) or alpha-amino-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors in these cells. QA, ibotenate and trans-1-aminocyclopentyl-1,3-dicarboxylate (ACPD) evoked dose-dependent inositol phosphate formations with EC50 values of 0.3, 6.7 and 29 microM, respectively. QA and ibotenate had the same maximal effect (295.7 +/- 17.9% of basal, n = 6) whereas the efficacy of ACPD was somewhat lower (70.2 +/- 8.9% of the maximal quisqualate effect, n = 4). The QA-, ibotenate- and ACPD-induced maximal effects were not additive, and the inositol phosphate formations induced by high concentrations of L-aspartate (L-ASP), AMPA, kainate (KA) and domoate (DO) (100 microM or higher) were also not additive. The inositol phosphate responses induced by all these agonists were totally blocked by the phorbol ester phorbol 12,13-dibutyrate (PdBu), but not by atropine or prazosin suggesting that all these substances were able to stimulate the Qp excitatory amino acid receptor in striatal neurons. Of the excitatory amino acid receptor antagonists tested, only D,L-2-amino-3-phosphonopropionate (D,L-AP3) inhibited QA-induced InsP formation in a competitive manner (mean pKi = 4.45 +/- 0.43, n = 4). However, this drug was also a partial agonist of the Qp receptor since it stimulated the inositol phosphate formation. We found that D,L-AP3 also inhibited NMDA-induced calcium increase, in a competitive manner (mean pIC50 = 4.34 +/- 0.22, n = 8, and mean pKi = 3.7 +/- 0.11, n = 5). The Qp excitatory amino acid receptor in striatal neurons therefore closely resembles Qp receptors with high potency for agonists as described in striatal and retinal slices and synaptoneurosomes, and has several pharmacological differences compared to the Qp receptors which have low potency for agonists described in hippocampal and cortical slices, cerebellar granule cells, astrocytes and rat brain mRNA-injected oocytes.

Cholinergic inositol phosphate formation in striatal neurons is mediated by distinct mechanisms.

In murine striatal neurons devoid of functional synapses (6 days in vitro) the cholinergic agonists carbachol and arecoline evoked dose-dependent inositol phosphate (InsP) responses with mean log EC50s of -4.1 +/- 0.5 and -4.48 +/- 0.1, respectively. Carbachol (1 mM) and arecoline (1 mM) responses were insensitive to tetrodotoxin, a voltage-sensitive Na+ channel blocker, and were blocked by pirenzepine with relatively low affinity (logIC50 = -5.9 +/- 0.3 for the carbachol response and logIC50 = -5.8 +/- 0.3 for the arecoline response). After synaptogenesis (13 days in vitro) the maximal carbachol effect doubled whereas the arecoline response remained unchanged. This additional effect was sensitive to tetrodotoxin and the voltage-dependent Ca2+ channel blocker, omega-conotoxin. The tetrodotoxin-sensitive carbachol response was blocked by lower concentrations of pirenzepine than the tetrodotoxin-insensitive carbachol response. More than 75% of the InsP response evoked by low concentrations of muscarine (1 and 10 microM) was sensitive to tetrodotoxin whereas only 38% of the InsP response stimulated by 1 mM of muscarine could be blocked by tetrodotoxin. These results suggest that there are at least two different mechanisms (depending on the stage of development), activated most probably by two different muscarinic receptors responsible for the carbachol-induced InsP formation in striatal neurons.

The glutamate receptor of the Qp-type activates protein kinase C and is regulated by protein kinase C.

In striatal neurons in primary culture quisqualate potently stimulated the formation of inositol phosphates via a metabotropic receptor we recently termed Qp in order to distinguish it from the classical ionotropic quisqualate receptor termed Qi. Here we show that 10 microM of quisqualate activated in a rapid and transient manner protein kinase C as assessed by its translocation from the cytosolic to the membrane fraction. As 10 microM alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA), the Qi specific agonist, was without effect, this translocation was most probably mediated by the Qp receptor. Phorbol 12,13-dibutyrate blocked in a dose-dependent manner the Qp receptor-induced inositol phosphate formation (IC50 = 2 +/- 0.4 nM). The inactive ester 4 alpha-phorbol-12,13-didecanoate was without effect. Very low concentrations of staurosporine completely reversed the phorbol 12,13-dibutyrate-induced blockade (IC50 = 2.2 +/- 1.3 nM). It can therefore be concluded that the Qp receptor is able to activate protein kinase C and that the activity of this metabotropic receptor is regulated by protein kinase C.